Fortrea Holdings (FTRE) Liabilities and Shareholders Equity (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Liabilities and Shareholders Equity came in at $2.7 billion in Q2 2026, down 4.24% YoY from $2.8 billion in Q2 2025, and up 1.17% on a QoQ basis from $2.7 billion in Q1 2026.
Fortrea Holdings (FTRE) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $2.7 billion in Q2 2026.
- Quarterly Liabilities and Shareholders Equity fell 4.24% year-over-year to $2.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $10.9 billion (down 17.75% YoY) and the FY2025 annual result came in at $2.7 billion, down 24.13% from the prior year.
- Liabilities and Shareholders Equity climbed to $2.7 billion in Q2 2026, from $2.7 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $4.4 billion in Q2 2023 to a low of $2.7 billion in Q1 2026.
- A 5-year average of $3.5 billion and a median of $3.6 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity climbed 1.04% — and 2025, when it fell 26.39%.
- Tracing FTRE's Liabilities and Shareholders Equity over 5 years: stood at $4.3 billion in 2022, then gained by 1.04% to $4.3 billion in 2023, then declined by 17.39% to $3.6 billion in 2024, then fell by 24.13% to $2.7 billion in 2025, then fell by 0.03% to $2.7 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $2.7 billion (Q2 2026), $2.7 billion (Q1 2026), and $2.7 billion (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn | 2.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.71 Bn |
| Mar 31, 2026 | 2.68 Bn |
| Dec 31, 2025 | 2.72 Bn |
| Sep 30, 2025 | 2.74 Bn |
| Jun 30, 2025 | 2.84 Bn |
| Mar 31, 2025 | 3.12 Bn |
| Dec 31, 2024 | 3.58 Bn |
| Sep 30, 2024 | 3.66 Bn |
| Jun 30, 2024 | 3.57 Bn |
| Mar 31, 2024 | 4.24 Bn |
| Dec 31, 2023 | 4.33 Bn |
| Sep 30, 2023 | 4.32 Bn |
| Jun 30, 2023 | 4.36 Bn |
| Dec 31, 2022 | 4.29 Bn |